Riboxin-Ferein

Quick links

Choose a section

Quick links to important sections

Advertisements

Riboxin-Ferein

Selected form

Advertisements
Advertisements

Overview of Riboxin-Ferein

What is Riboxin-Ferein?

Riboxin-Ferein is a pharmaceutical preparation containing the active substance Inosine. It belongs to a class of metabolic agents designed to support and stimulate biochemical processes within the body's tissues. Historically, it has been categorized as an anabolic drug due to its role in energy metabolism, though it does not possess the hormonal properties associated with steroids.

Composition and Mechanism

The primary component, Inosine, is a naturally occurring nucleoside that serves as a precursor to adenosine triphosphate (ATP). ATP is the fundamental energy currency of biological cells. Riboxin-Ferein is intended to facilitate metabolic stability under conditions where oxygen supply may be limited or metabolic demand is high.

Its mechanism of action involves several key physiological pathways:

  • Metabolic Regulation: It participates in glucose metabolism and promotes the activation of pyruvic acid, which is essential for normal tissue respiration.
  • Energy Balance: By stimulating the synthesis of nucleotides, it helps maintain energy levels within cells, particularly in the myocardium (heart muscle) and skeletal muscles.
  • Microcirculation Support: It is thought to influence the rheological properties of blood, potentially aiding in the maintenance of healthy blood flow at the capillary level.

Intended Physiological Effects

Riboxin-Ferein is primarily utilized to support the heart and other organs during periods of metabolic stress. Its presence in the body is associated with the following effects:

  1. Antihypoxic Properties: It assists tissues in functioning more efficiently when oxygen availability is reduced.
  2. Cardioprotective Support: It is often used to support the heart muscle's ability to contract and relax properly by ensuring a steady supply of metabolic precursors.
  3. Tissue Regeneration: By promoting protein synthesis and cell division, it may aid in the natural recovery processes of various tissues.

In clinical practice, this agent is recognized for its role as a metabolic cofactor, providing the necessary building blocks for cellular energy and structural integrity.

Regulatory References

  1. Inosine - MeSH
Advertisements

What side effects are possible with Riboxin-Ferein?

Possible Side Effects and Safety Information

The regulatory safety profile for Riboxin-Ferein (Inosine) is structured around its metabolic action as a purine nucleoside. The most characteristic and Very Common safety finding, documented in official sources, is a resulting increase in blood uric acid and urine uric acid concentrations. This metabolic effect is typically noted as transient.

Adverse reactions are classified by frequency across several physiological systems:

  • Common Reactions (occurring in 1 to 10 out of 100 people) primarily involve the Nervous System and Gastrointestinal system, including headache, dizziness (vertigo), nausea, vomiting, and epigastric discomfort. Skin reactions such as rash and pruritus (itching) are also common.

  • Uncommon Reactions (occurring in 1 to 10 out of 1,000 people) include diarrhoea, constipation, insomnia, and somnolence (drowsiness).

Serious Adverse Reactions and Safety Limitations

Official regulatory documents note that severe hypersensitivity reactions are documented, although their frequency is classified as Not Known. These serious reactions include anaphylactic shock and angioedema.

The drug's use is subject to specific constraints due to its metabolic activity. It is contraindicated for individuals with a known hypersensitivity to Inosine and those with pre-existing conditions like Hyperuricaemia or manifest Gout. Caution is also advised for use in individuals with impaired renal function or a history of urolithiasis (kidney stones).

For long-term treatment (three months or longer), regulatory labeling mandates the regular monitoring of blood and urine uric acid levels, as well as renal and hepatic function parameters.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation confirms that no specific clinical experience of acute overdose with Riboxin-Ferein (Inosine) has been reported. Due to this lack of specific data, emergency medical care is always required if excessive exposure is suspected.

Based on non-clinical data, serious adverse effects resulting from overdose are generally considered unlikely, except for documented metabolic changes. The single consistent physiological finding associated with high exposure is the transient elevation of serum and urinary uric acid levels (hyperuricemia). This metabolic change directs the required monitoring strategy.

Emergency Actions and Management Protocols

When to Seek Help: You must seek immediate medical attention and contact emergency services if any unexpected or severe signs develop following a suspected overdose.

Management Protocols: Management is explicitly restricted to symptomatic and supportive measures. No specific antidote for Riboxin-Ferein overdose is documented in official labeling. Continuous observation should include monitoring of serum and urinary uric acid levels. The known risk of uric acid elevation is particularly relevant in males and the ageing population, a factor that must be considered during medical assessment.

Advertisements

Therapeutic Uses of Riboxin-Ferein

What Riboxin-Ferein Treats: Main Uses and Benefits

Riboxin-Ferein may be considered relevant in contexts where the heart muscle (myocardium) is experiencing metabolic strain, which is a key characteristic of conditions like Ischemic Heart Disease (IHD) or the recovery phase after a myocardial infarction. This metabolic assistance is generally applied when supportive symptom management is appropriate for conditions involving heightened physiological stress. This supportive assistance helps maintain functional stability and contributes to easing the overall symptom load during periods of heightened symptoms.


The medication may assist with conditions presenting with systemic or localized discomfort, which includes conditions marked by increased physiological stress, such as IHD, post-myocardial infarction states, myocardiodystrophy (due to stress or infection), heart rhythm disturbances (e.g., from drug toxicity), and chronic liver pathologies like Hepatitis, Cirrhosis, and Fatty Liver Disease (Steatosis). This medication may be applied to provide supportive therapeutic benefit in liver pathologies and specialized settings, such as addressing conditions where functional stability becomes affected during surgical procedures.


Quick Fact: Supports Management of Symptoms Linked to Organ Stress (The medication supports general well-being and assists with maintaining functional stability when symptoms interfere with routine activities, particularly in the heart and liver.)

Advertisements

Eligibility and Restrictions for Use

Riboxin-Ferein (Inosine) eligibility is defined by official regulatory documentation, primarily based on the drug’s potential to affect purine metabolism and its lack of established safety data in certain groups.


Populations Who Must Not Use (Contraindicated)

Classification Restricted Group/Condition
Absolute Contraindication Known Hypersensitivity to inosine or excipients.
Absolute Contraindication Patients with active Gout or high blood levels of Hyperuricemia.

Populations Requiring Restriction or Caution

Classification Restricted Group/Condition
Not Recommended Pregnancy and Lactation, due to lack of established safety data.
Not Established Children and Adolescents (under 18 years), as efficacy and safety data are insufficient.
Conditional Use Patients with Renal Impairment or a history of urolithiasis (kidney stones), often requiring dose adjustment and close monitoring.
Conditional Use Patients with Hepatic Impairment, requiring special caution and liver function monitoring.

This structure ensures that use is avoided in individuals with pre-existing purine metabolism disorders and in vulnerable populations where the drug's safety profile is not fully documented.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Riboxin-Ferein (Inosine) is a purine nucleoside whose official interaction profile is primarily defined by the consequences of its metabolism and specific regulatory timing constraints. The resulting interaction statements are officially classified in documentation as requiring caution or timing separation.

Interacting Substance Categories and Restrictions:

  • Xanthine Oxidase Inhibitors: Co-administration with agents such as Allopurinol is a documented pharmacodynamic interaction requiring caution. This effect is driven by the catabolism of Inosine to uric acid, which results in an additive influence on systemic uric acid levels.
  • Uricosuric Agents: Certain agents, including specific diuretics (like hydrochlorothiazide or furosemide), require caution in co-administration as these substances may affect the excretion rate of Inosine metabolites.
  • Immunosuppressive Agents: Official regulatory documents define a strict, timing-based constraint: Inosine may be administered after but not concomitantly with these agents.
  • Zidovudine (AZT): This co-administration represents a documented exposure-modifying interaction. It officially results in increased Zidovudine nucleotide formation and increased plasma bioavailability of the antiviral agent.

Population-Specific Regulatory Caution:

Due to Inosine’s metabolic pathway, which may lead to a transient elevation of serum and urinary uric acid, caution is formally required in populations with pre-existing conditions such as gout, hyperuricaemia, urolithiasis, or impaired renal function.

Advertisements

Mechanism of Action

How Riboxin-Ferein Works

Riboxin-Ferein's active component, Inosine, influences cellular function through three primary mechanisms, beginning with its role as a direct precursor in the Purine Salvage Pathway. By serving as a substrate for key enzymes like Hypoxanthine Phosphoribosyltransferase ( HPRT), it promotes the synthesis and recycling of Adenosine Triphosphate (ATP), the fundamental currency of cellular energy. This action is crucial for impacting metabolic dynamics and affecting the energy balance within tissues under conditions of metabolic deficit or low oxygen tension.

Inosine and its metabolites also act as modulators or partial agonists at various Adenosine Receptors ( A1, A2 A, etc.), components of the purinergic signaling system. Through this interaction, the molecule influences vascular tone, leading to relaxation of the smooth muscle and resulting in modulation of local blood flow and oxygen delivery, a factor in its overall physiological action.

Furthermore, Inosine contributes to cytoprotection by limiting resource consumption (through potential PARP enzyme inhibition) and by generating the endogenous antioxidant, Uric Acid, during its breakdown. These actions contribute to the cell's natural defenses against oxidative stress, impacting the structural integrity of tissues with high metabolic demands.

Advertisements

Dosage and Administration Information

How to Use Riboxin-Ferein

Riboxin-Ferein (Inosine) usage is governed by administration principles focusing on the oral route and specific dosing parameters. The medicine is primarily available for systemic delivery as a film-coated tablet or capsule.

Official Administration Directives

The required usage patterns ensure consistency in the way the purine nucleoside is delivered throughout the day.

Usage Parameter Instruction
Administration Route Oral, using the tablet or capsule formulation.
Dosing Range The total daily dose for adults typically ranges from 3 g to 4 g. The maximum daily intake is established at 4 g.
Frequency Pattern The total daily dose must be administered in three to four equally divided portions taken throughout the waking hours.
Intake Context Administration is flexible and can occur with or without food.
Preparation Tablets may be crushed and dissolved in a small amount of liquid for patients who have difficulty swallowing them whole.

Dosing Adjustments and Duration

The instructions define how the duration of use is structured and detail adjustments for specific patient groups.

  • Course Duration: Use is typically structured around short courses lasting 5 to 14 days for acute needs, though extended or cyclical use is part of the established protocol for certain long-term applications.
  • Pediatric Use: Dosage is based on body weight, with a regimen of 50 mg/kg/day administered in divided doses, not exceeding the maximum adult dose.
  • Older Adults: No specific dose adjustment is universally mandated in the prescribing information; the standard adult regimen is generally applicable.

These administration guidelines provide the framework for consistent and standardized delivery of Riboxin-Ferein.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Riboxin-Ferein


Evidence for Use in Supportive Heart Conditions

Riboxin-Ferein was studied in research contexts involving conditions such as Ischemic Heart Disease (IHD) and periods following a myocardial infarction. The research primarily consists of preclinical investigations using animal models that created cardiac injury scenarios, alongside human studies focusing on the compound's systemic presence in the body.

Studies focused on surrogate markers of cell damage (such as infarct size in animals), measurements of ventricular function, and assessments using patient symptom and function scales. Findings describe patterns observed in the studies where measurements related to organ functional status were reported in injured animal models. However, the certainty remains low regarding the use of this compound in these specific heart conditions. Evidence is limited from large-scale, double-blind Randomized Controlled Trials (RCTs) that meet current regulatory standards and are necessary to fully understand clinical outcomes.


Evidence for Use in Chronic Liver Pathologies

Research was also observed in studies exploring conditions characterized by fluctuating or episodic manifestations in the liver, including chronic liver pathologies like Hepatitis, Cirrhosis, and Fatty Liver Disease. The majority of the evidence research describes comes from preclinical studies using animal models that reflect different types of liver injury.

Studies monitored outcomes related to systemic or functional imbalance, such as biochemical markers of liver function and outcomes linked to inflammatory states in animals. Data from human applications largely stem from historical observational reports or smaller trials, rather than recent, controlled studies. The evidence quality varies across studies, and the data are still emerging for key clinical questions. Because the evidence relies heavily on preclinical animal models, the results apply only to the populations studied and do not necessarily translate to a clear outcome for human patients.


What is Still Uncertain About the Research Evidence

Limited information for long-term outcomes or the durability of observed responses is available for the indications related to heart and liver conditions. Comparative evidence is lacking from modern, large-scale, randomized trials needed to establish definitive conclusions for its traditionally studied indications. Sample sizes were modest in many of the human studies, meaning that findings describe group patterns, not personal outcomes. Research is ongoing in related metabolic areas, but the overall certainty remains low for long-term clinical outcomes in the main indications the compound was studied for.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Riboxin-Ferein (FAQ)

Q: What is the main reason doctors prescribe Riboxin-Ferein?

According to official regulatory documents, Riboxin-Ferein is formally indicated as a metabolic agent. Its use is described in the context of specific conditions involving myocardial (heart muscle) energy imbalance, such as Ischemic Heart Disease (IHD) and during recovery after a myocardial infarction. The medicine has also been explored in relation to certain chronic liver pathologies.

Q: Is Riboxin-Ferein the same as I Riboflavin?

No, Riboxin-Ferein is not the same as Riboflavin. The active substance in this medicine is Inosine, which is classified as a purine nucleoside and a metabolic agent. Riboflavin is chemically known as Vitamin B₂ and is a different substance with unrelated properties.

Q: Does Riboxin-Ferein help with general fatigue or just heart problems?

Official therapeutic indications for Riboxin-Ferein are restricted to specific conditions like myocardial energy imbalance and certain liver pathologies. It is important to note that the medicine is not officially indicated or approved by regulatory bodies for the treatment of general, non-specific fatigue.

Q: Are there any long-term effects of taking Riboxin-Ferein?

Official regulatory instructions provide specific guidance for continuous use of Riboxin-Ferein lasting three months or longer. The product label specifies that regular monitoring of blood and urine uric acid levels and renal (kidney) and hepatic (liver) function parameters is required for this long-term use.

Q: Are there any specific foods or drinks to avoid while using Riboxin-Ferein?

Official regulatory guidance on administration states that the medicine can be taken flexibly, either with or without food. There are no specific foods or drinks that are formally prohibited or required to be avoided in the medicine's regulatory documents.

Q: Is Riboxin-Ferein safe for older adults (seniors)?

Official prescribing information indicates that no specific dose adjustment is universally mandated for older adults. The standard adult regimen is generally applicable to this population group. However, conditions common in older adults, such as impaired kidney function, may require caution and monitoring.

Q: Why do some people confuse Riboxin-Ferein with energy supplements?

This potential confusion stems from the medicine's mechanism of action, which is described in official documents. Riboxin-Ferein’s active component, Inosine, acts as a precursor in a metabolic process that helps promote the synthesis of Adenosine Triphosphate (ATP), the body’s fundamental source of cellular energy.

Q: If I miss a planned use of Riboxin-Ferein, what happens?

Patient information leaflets usually contain directions for missed uses. These leaflets generally state that the missed dose may be taken as soon as remembered. However, if it is almost time for the next planned use, the typical instruction is to skip the missed dose and resume the normal administration schedule.

Q: Is Riboxin-Ferein classified as a vitamin or a drug?

Riboxin-Ferein is formally classified as a pharmaceutical preparation and a medicinal product. It functions as a metabolic agent. Its active component, Inosine, is a naturally occurring purine nucleoside that influences the body's energy and chemical processes.

Q: Does Riboxin-Ferein contain any common allergens like gluten or lactose?

The official regulatory document for the specific formulation contains a complete list of excipients (inactive ingredients) in Section 6.1. This is where information regarding the presence of common allergens, such as gluten or lactose, is formally listed.

Q: Why is Riboxin-Ferein used in different medical specialties?

The use of the medicine in different areas, such as conditions related to the heart and the liver, is linked to its fundamental mechanism of action. The compound’s role is to provide metabolic support by promoting cellular energy (ATP synthesis) and stabilizing the internal environment of tissues that are under stress or experiencing energy deficits.

Q: Is Riboxin-Ferein generally considered well-tolerated?

The tolerability of the medicine is defined by its regulatory safety profile, which categorizes adverse reactions by frequency. The most characteristic very common effect is a transient increase in blood uric acid. Other common reactions include gastrointestinal upset, headache, and skin reactions like rash.

Q: What is the primary way Riboxin-Ferein is eliminated from the body?

According to official pharmacokinetic documents, the active substance, Inosine (a purine nucleoside), is metabolized within the body via the natural purine catabolic pathway. This metabolic breakdown process results in the formation and eventual elimination of uric acid.

Q: Do studies support the use of Riboxin-Ferein for improving tissue oxygen supply?

The official description of the drug’s mechanism of action states that it influences vascular tone, which modulates local blood flow and oxygen delivery to tissues. Research has primarily explored and documented this functional action in the context of conditions related to myocardial ischemia (inadequate blood supply to the heart muscle).

Q: What does the regulatory label say about using Riboxin-Ferein in different climate conditions?

Regulatory labels define storage conditions, which include requirements for the product to be stored at a temperature not exceeding 25 C (77 F). The container must also be kept tightly closed in a dry place and protected from light.

Q: Can Riboxin-Ferein cause joint pain or muscle stiffness?

The medicine’s most characteristic metabolic effect is a transient increase in uric acid levels, which is a very common finding. Because of this, the medicine is formally contraindicated in individuals with active Gout, a condition involving severe inflammation and pain in the joints.

Q: Is there a known antidote for a very high use of Riboxin-Ferein?

Information regarding specific actions to take in the event of ingestion exceeding the maximum recommended use is defined in the regulatory documentation. This section covers overdose management, including treatment protocols and any known specific antidotes.

Advertisements

How should Riboxin-Ferein be stored and disposed of?

How to Store and Dispose of Riboxin-Ferein

Official regulatory guidelines define specific storage and disposal requirements for Riboxin-Ferein (Inosine) to maintain its stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 25 C
Protection Must be kept in a dry place and a place protected from light
Container The container must be kept tightly closed to prevent moisture exposure
Child Safety The medicine must be stored out of the reach and sight of children

Disposal Instructions

Disposal of unused or expired Riboxin-Ferein must adhere to local pharmaceutical waste regulations. The product should not be disposed of by emptying into drains or wastewater; instead, it must be discarded through approved collection methods, as specified by local authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Riboxin-Ferein found in:

A-Z Index: